IDEXX Laboratories, Inc. $IDXX Shares Acquired by Mather Group LLC.

Mather Group LLC. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 92.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,462 shares of the company’s stock after buying an additional 702 shares during the period. Mather Group LLC.’s holdings in IDEXX Laboratories were worth $784,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. lifted its position in shares of IDEXX Laboratories by 97.0% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 1,838 shares of the company’s stock worth $760,000 after purchasing an additional 905 shares during the last quarter. Centaurus Financial Inc. lifted its holdings in IDEXX Laboratories by 23.3% during the 4th quarter. Centaurus Financial Inc. now owns 280 shares of the company’s stock worth $116,000 after buying an additional 53 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $11,226,000. 111 Capital bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $866,000. Finally, Wellington Management Group LLP raised its position in shares of IDEXX Laboratories by 161.2% during the 4th quarter. Wellington Management Group LLP now owns 195,369 shares of the company’s stock valued at $80,773,000 after acquiring an additional 120,558 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IDXX shares. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. BTIG Research lifted their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price on the stock. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $649.44.

Insider Activity at IDEXX Laboratories

In other news, EVP Michael Lane sold 8,411 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company’s stock, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the sale, the chief executive officer owned 83,311 shares in the company, valued at approximately $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 in the last ninety days. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 1.4%

IDEXX Laboratories stock opened at $618.17 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $49.45 billion, a price-to-earnings ratio of 51.47, a PEG ratio of 4.06 and a beta of 1.56. The firm has a 50-day moving average price of $623.25 and a two-hundred day moving average price of $525.93.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.